Which Pharma Firm Increases US Prices The Most?

Transparency reports from companies aim to change conversation from prices to discounts, but also invite comparisons. Lilly, for example, saw a higher average list price increase in 2016 than Merck and Janssen, but its net prices grew by less than the others.

Are pharma company efforts to disclose their pricing activities having an impact on public or political perception of their practices in the US? Nothing dramatic yet, it seems, but the flow of reports does invite some interesting comparisons between the firms themselves.

Eli Lilly & Co. is the latest major pharma company to issue a pricing transparency report revealing its average price increases over the past five years. While its 2016...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Stock Watch: Q1 Sales Trends And Forex Muddle Pharma Outlook

26 May 2025

• By Andy Smith

Pharma firms tended to downplay first-quarter trends in full-year guidance. However, raised guidance seems fragile amid ongoing foreign exchange effects and Medicare Part D redesign pressures.

HHS Intensifies Pressure On Pharma With MFN Pricing Benchmark

20 May 2025

• By Jessica Merrill

The Trump administration released more details on “most favored nation” price targets drug companies are expected to apply to US drug prices.

Lupin CEO On Trump’s Most Favored Nation Policy, Tariffs, Firm’s Five-Year Plan

16 May 2025

• By Vibha Ravi

Lupin CEO Vinita Gupta speaks on Trump’s most favored nation policy, the Inflation Reduction Act’s “pill penalty” and other developments in the US, a major market for the company. The company also outlines a five-year plan focused on complex generics and technology platforms.

Most Favored Nation Policy ‘Lazy, Misguided,’ But US Price Reforms Politically ‘Inevitable’

15 May 2025

• By Cathy Kelly

Policy experts and pharma executives react to President Trump’s executive order on “equalizing” drug prices between the US and comparable nations at the ISPOR 2025 conference.

Merck & Co./Daiichi Pull Patritumab Deruxtecan BLA On Disappointing OS

29 May 2025

• By Jessica Merrill

Patritumab deruxtecan is the lead antibody drug conjugate in a $22bn deal signed between the two partners, with the decision marking a disappointing setback